Today we can announce that we have finalized the Sencell Clinical Development Study (LFC-SEN-001) and it reveals accurate sensor performance in human subjects. - This is a very important step in the right direction to develop the next generation Continuous Glucose Monitor (CGM) for people with diabetes, says CEO Joacim Holter.
In this first clinical development study, the osmotic pressure based continuous glucose sensor was clearly shown to track subcutaneous glucose concentrations at least as good as the commercially available needle sensors.
- The study output is as good as we had hoped for, and the production and product development has been even better than expected throughout the study. Both in an academic and strategic setup it is important for us to ensure that our groundbreaking results are communicated clearly to the diabetes technology community, and we have therefor decided to disclose our scientific results, says Holter. The detailed results of this first-in human clinical study with Sencell will be presented during the scientific program of the upcoming American Diabetes Conference in San Diego on June 24th.
- Beside successful results we are incredibly satisfied with how the organization has overcome very challenging issues. Holter reminds that the sensor company operates with complex and pioneering sensor technology, while always having a focus on ensuring high quality at all stages of the process. - The Lifecare team should be very proud of what they have achieved so far, says Holter.
The clinical performance characteristics of these wired prototypes provide us with strengthened and valuable knowledge for the next steps of product development. - We strongly believe that this forms a solid knowledge base when we develop the sensor with integrated wireless data transmission, says Holter.
In April Lifecare announced that a sensor first used in our Clinical Development Study had confirmed an operational longevity of 12 weeks in a continued laboratory (in vitro) set up. - All this together is absolutely a breakthrough, considering today's CGM technology. Hopefully this is a significant step towards Lifecare’s goal of contributing to helping people with diabetes to live a normal life.
______________________________________________________
Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare´s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body.
______________________________________________________
Contact: Joacim Holter, CEO, tel. +47 40059050, epost: joacim.holter@lifecare.no
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Joacim Holter, CEO at Lifecare AS, on 11 Mai 2023 at 10:40 CET